XPR – Lifestyle Demo
Author:
AgomAb Therapeutics N.V.
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
April 23, 2026
Agomab Receives U.S. Patent for AGMB-447, its Inhaled Lung-restricted Small Molecule Inhibitor of ALK5 in Development for the Treatment of Idiopathic Pulmonary Fibrosis
March 26, 2026